Showing 41-50 of 107 results for "".
- First Austrian Skin Cancer Patients Treated with Rhenium-SCT in New Studyhttps://practicaldermatology.com/news/first-austrian-skin-cancer-patients-treated-with-rhenium-sct-in-new-study/2461110/The first Austrian patients have been treated in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT– for the treatment of non-melanoma skin cancer), according to OncoBeta GmbH. "This is an important step for better understanding efficacy and patient outcomes…
- Novan, Inc. Acquires EPI Healthhttps://practicaldermatology.com/news/novan-inc-acquires-epi-health/2461106/EPI Health is now a Novan Company. The EP Group today announced the acquisition of EPI Health, LLC by Novan, Inc. EPI Health is a leading company in the US dermatology sector with an established sales force and commercial team with existing, deep market relationships across the dermatology commun…
- Cyspera Launches New Three-Step System to Treat Hyperpigmentationhttps://practicaldermatology.com/news/cyspera-launches-new-three-step-system-to-treat-hyperpigmentation/2461083/Scientis is launching Cyspera Intensive System, a new three-product system designed to improve hyperpigmentation. Cysteamine inhibits several steps in the melanogenesis pathway while also working as antioxidant to protect against free radicals. The Cyspera Intensive System is formulated with a pro…
- Neutrogena Announces New "Heroes of Skin Health Equity" Initiativehttps://practicaldermatology.com/news/neutrogena-announces-new-heroes-of-skin-health-equity-initiative/2461057/Neutrogena is launching its new Heroes of Skin Health Equity initiative, the brand’s latest effort aimed at closing the gap to skin health equity for those with Black and brown skin. The brand will publicly recognize the work of individuals who are striving to make the world of skincare more equi…
- New Patient Satisfaction Data from Dermavant's PSOARING 3 Trial of Tapinarof in Adults with Plaque Psoriasishttps://practicaldermatology.com/news/new-patient-satisfaction-data-from-dermavants-psoaring-3-trial-of-tapinarof-in-adults-with-plaque-psoriasis/2461043/Results from a patient satisfaction questionnaire in the long-term, open-label Phase 3 PSOARING 3 extension study of tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults demonstrated consistent high rates of satisfaction and positive perception of treatment with tapinarof a…
- Derms Give Back: Destination Healthy Skin Wraps Up Its 2021 Journeyhttps://practicaldermatology.com/news/derms-give-back-destination-healthy-skin-wraps-up-its-2021-journey/2461003/Destination Healthy Skin, The Skin Cancer Foundation’s mobile skin cancer education and screening program, conducted 920 free skin cancer screenings aboard the Foundation’s 38-foot Destination Healthy Skin RV. Approximately 4,000 participants attended events around the country and received The Sk…
- Dermavant: First Patient Dosed in Phase 3 Study of Tapinarof in ADhttps://practicaldermatology.com/news/dermavant-first-patient-dosed-in-phase-3-study-of-tapinarof-in-ad/2460925/The first patient has been dosed in the Phase 3, double-blind, vehicle-controlled pivotal study of tapinarof for the treatment of atopic dermatitis (AD). Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development by Dermavant as a once-daily, ster…
- OncoBeta Launches Study of Rhenium-SCT for Skin Cancerhttps://practicaldermatology.com/news/oncobeta-launches-study-of-rhenium-sct-for-skin-cancer/2460909/OncoBeta GmbH is starting a phase IV international multi-centre study evaluating the complete response rate of patients with non-melanoma skin cancer after treatment with Rhenium-SCT. The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the …
- Dermatologist Named as AMA President-Electhttps://practicaldermatology.com/news/dermatologist-named-as-ama-president-elect/2460835/Jack Resneck Jr, MD, a dermatologist from the San Francisco Bay Area, is the new president-elect of the American Medical Association (AMA). Following a year-long term as president-elect, Dr. Resneck will assume the office of AMA president in June 2022. “It is truly an honor to be elected by my pee…
- Cosentyx Now Approved for Psoriasis in Children as Young as Sixhttps://practicaldermatology.com/news/cosentyx-now-approved-for-psoriasis-in-children-as-young-as-six/2460815/Cosentyx® (secukinumab) from Novartis is now FDA approved for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. This is the first approval for Cosentyx in a pediatric population in the US. Cosent…